# Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

> **NCT00395434** · PHASE1 · COMPLETED · sponsor: **Mateon Therapeutics** · enrollment: 20 (estimated)

## Conditions studied

- Tumors

## Interventions

- **DRUG:** Combretastatin A4 Phosphate (CA4P)
- **DRUG:** Bevacizumab (Avastin)

## Key facts

- **NCT ID:** NCT00395434
- **Lead sponsor:** Mateon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2011-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00395434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00395434, "Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00395434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*